


Clinical summary: The DYNAMIC study

# Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer<sup>1</sup>

Clinicians report the first results from the DYNAMIC study, which assessed the clinical benefit of MRD testing to inform therapeutic decisions for patients with stage II colorectal cancer.

## Background

In patients with stage II colon cancer, the benefit of adjuvant therapy and identification of patients who should receive it is unclear. Some clinical studies have reported promising observational results on the performance of circulating tumor DNA (ctDNA) as a biomarker to measure minimal residual disease (MRD) post surgery. The goal of the DYNAMIC study was to determine if ctDNA, as measured with an appropriate assay for MRD detection, could improve 1) the identification of patients to receive adjuvant therapy and 2) which patients might forgo it with minimal risk of recurrence. The DYNAMIC trial is the first to demonstrate clear clinical benefit of ctDNA-based MRD detection following surgery.



## Conclusions

DYNAMIC is the first study of its kind to assess the clinical benefit of MRD testing to guide adjuvant therapy. The findings demonstrate that there is a significant clinical benefit to utilizing MRD testing to guide adjuvant therapy in early-stage solid tumor patients.


<sup>1</sup> Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. *N Engl J Med.* 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075

# Make better decisions with better MRD testing

Next-generation ctDNA detection with unmatched sensitivity and specificity for confident MRD reporting.



## Haystack Oncology

Haystack MRD™ is a tumor-informed liquid biopsy-based test that begins with tissue-based whole-exome sequencing (WES) to identify patient-specific tumor mutations. A personalized MRD test is then developed to detect ctDNA from residual, recurrent, or resistant disease.



## Unmatched sensitivity

Haystack's Duo™ sequencing chemistry is a later version of the Safe-SeqS chemistry used in the DYNAMIC study. Built by the team that developed Safe-SeqS, Duo significantly reduces noise to detect even a single ctDNA molecule out of a million wild type molecules in the blood to deliver unmatched sensitivity down to 0.0001% tumor fraction.



## See what other tests can't

Haystack MRD testing provides **one-in-a-million** ctDNA detection sensitivity to deliver the most comprehensive clinical information to help you make the right decisions to achieve favorable outcomes for your patients.

Learn more at [haystackoncology.com](https://haystackoncology.com)

Or email us at [info@haystackoncology.com](mailto:info@haystackoncology.com)

